Apart from a control arm, the study had an arm treated with temozolomide, which is a standard therapy for glioma, on the first 5days at 25mg/kg IP, a third arm treated with an experimental drug which inhibits the BMI1 gene, which is a target to prevent tumor self-renewal [26], at maximum tolerated dose (MTD) PO twice weekly x 5, an and a fourth arm treated with combination of the two agents given at same doses and schedules. Here, BMI1 is linked to neoplasm.